Our data were consistent with previous studies, which suggested that strategies to deplete Treg cells in breast cancer patients [42, 43] may also be beneficial by reducing local immunosuppression and removing a primary source of RANKL required for tumor metastasis. The gene discussed is TNFSF11; the disease is breast cancer.